Archives

  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-08
  • 2025-07
  • 2025-06

    • Beta-Lipotropin (1-10), Porcine Mechanisms, Clinical Applica

    2025-08-25

    Beta-Lipotropin (1-10), Porcine: Mechanisms, Clinical Applications, and Research Perspectives

    Introduction
    Beta-Lipotropin (1-10), porcine, is a synthetic peptide fragment derived from the N-terminal region of beta-lipotropin, a pro-opiomelanocortin (POMC) cleavage product primarily produced in the anterior pituitary gland. Beta-lipotropin itself is a 90-amino acid polypeptide with diverse biological activities, including lipid mobilization and opioid-like effects (Li et al., 2016, Peptides). The (1-10) fragment comprises the first ten amino acids of the full-length peptide, and research has increasingly focused on its unique bioactivity, particularly in the context of neurobiology and metabolic regulation.

    Mechanistically, Beta-Lipotropin (1-10) is believed to interact with specific receptors in the central nervous system, modulating neurotransmitter release and influencing neuroendocrine pathways (Smith & Funder, 1988, Endocrinology). Its sequence overlaps with that of met-enkephalin, an endogenous opioid peptide, suggesting potential roles in pain modulation, stress response, and neuroprotection. The porcine variant is of particular interest due to its high sequence homology with human beta-lipotropin, making it a valuable research tool for translational studies.

    [Related: bafilomycin a1 solubility] Clinical Value and Applications
    The clinical value of Beta-Lipotropin (1-10), porcine, lies in its multifaceted biological activities and its potential as a research tool for understanding neuropeptide function. Its applications span several domains:

    1. **Neuroscience Research**: Beta-Lipotropin (1-10) has been shown to influence synaptic transmission and neuroplasticity, making it relevant for studies on neurodegenerative diseases, mood disorders, and pain mechanisms (Kastin et al., 1981, Brain Research).
    2. **Metabolic Regulation**: The parent molecule, beta-lipotropin, is involved in lipid mobilization and energy homeostasis. The (1-10) fragment is being investigated for its potential to modulate metabolic pathways, which could have implications for obesity and metabolic syndrome research (Li et al., 2016, Peptides).
    3. **Opioid System Modulation**: Given its structural similarity to enkephalins, Beta-Lipotropin (1-10) may serve as a model peptide for studying endogenous opioid signaling, with potential applications in pain management and addiction research (Smith & Funder, 1988, Endocrinology).
    4. **Neuroprotection**: Preliminary evidence suggests that Beta-Lipotropin (1-10) may exert neuroprotective effects in models of ischemia and neurotoxicity, supporting its use in preclinical studies of stroke and neurodegeneration (Zadina et al., 1997, J. Neurosci. Res.).

    [Related: MRTX-1133] Key Challenges and Pain Points Addressed
    Current treatments for neurodegenerative diseases, chronic pain, and metabolic disorders often suffer from limited efficacy, off-target effects, and significant side effects. Beta-Lipotropin (1-10), porcine, addresses several of these challenges:

    - **Specificity**: As a defined peptide fragment, Beta-Lipotropin (1-10) offers greater specificity in receptor targeting compared to broader-acting small molecules or full-length peptides, reducing the risk of off-target effects (Kastin et al., 1981, Brain Research).
    - **Translational Relevance**: The high sequence homology between porcine and human beta-lipotropin enhances the translational potential of preclinical findings, facilitating the development of human therapeutics (Li et al., 2016, Peptides).
    - **Novel Mechanisms**: By modulating endogenous opioid and neuroendocrine pathways, Beta-Lipotropin (1-10) provides a novel mechanism of action distinct from traditional pharmacotherapies, which may overcome resistance or tolerance issues seen with current drugs (Smith & Funder, 1988, Endocrinology).
    - **Research Tool Versatility**: The peptide’s defined structure and stability make it suitable for in vitro, ex vivo, and in vivo studies, supporting a wide range of experimental designs (APExBIO, 2024).

    [Related: ap20187 thermo fisher] Literature Review
    A growing body of literature supports the biological relevance and research utility of Beta-Lipotropin (1-10):

    1. **Kastin, A.J., et al. (1981). "Beta-lipotropin (1-10): Effects on behavior and pain sensitivity in rodents." Brain Research, 222(2), 345-352.**
    This seminal study demonstrated that Beta-Lipotropin (1-10) exerts significant analgesic effects in rodent models, supporting its role in endogenous opioid signaling.

    2. **Smith, A.I., & Funder, J.W. (1988). "Pro-opiomelanocortin processing in the pituitary: Insights from beta-lipotropin fragments." Endocrinology, 123(3), 1137-1145.**
    The authors detail the processing of POMC and the functional implications of its fragments, including Beta-Lipotropin (1-10), in neuroendocrine regulation.

    3. **Li, X., et al. (2016). "Beta-lipotropin and its fragments: Metabolic and neuroendocrine effects." Peptides, 78, 1-8.**
    This review highlights the metabolic and neuroendocrine activities of beta-lipotropin and its N-terminal fragments, emphasizing their translational potential.

    4. **Zadina, J.E., et al. (1997). "Neuroprotective effects of beta-lipotropin fragments in models of ischemic injury." Journal of Neuroscience Research, 50(5), 678-685.**
    The study provides evidence for the neuroprotective properties of Beta-Lipotropin (1-10) in cellular and animal models of ischemia.

    5. **Mains, R.E., et al. (1977). "Biosynthesis of beta-lipotropin and related peptides in the pituitary." Proceedings of the National Academy of Sciences, 74(7), 3014-3018.**
    This foundational work elucidates the biosynthetic pathways of beta-lipotropin and its fragments, laying the groundwork for subsequent functional studies.

    6. **APExBIO Technology LLC. (2024). "Beta-Lipotropin (1-10), porcine: Product information and research applications." Retrieved from https://www.apexbt.com/ss-lipotropin-1-10-porcine.html**
    The manufacturer provides technical details and research applications, supporting the peptide’s utility in experimental settings.

    7. **Bicknell, R.J., et al. (1981). "Opioid activity of beta-lipotropin fragments in the central nervous system." Neuropharmacology, 20(12), 1205-1212.**
    This paper explores the opioid-like activities of beta-lipotropin fragments, including analgesic and behavioral effects.

    Experimental Data and Results
    Experimental studies have elucidated several key properties of Beta-Lipotropin (1-10), porcine:

    - **Analgesic Activity**: Kastin et al. (1981) reported that intracerebroventricular administration of Beta-Lipotropin (1-10) in rodents produced dose-dependent analgesia, comparable to that of met-enkephalin. The effect was reversed by naloxone, confirming opioid receptor involvement.

    - **Neuroprotection**: Zadina et al. (1997) demonstrated that Beta-Lipotropin (1-10) reduced neuronal death in hippocampal slice cultures subjected to oxygen-glucose deprivation, suggesting a direct neuroprotective effect.

    - **Metabolic Effects**: Li et al. (2016) found that Beta-Lipotropin (1-10) modulated plasma lipid profiles and reduced adiposity in diet-induced obese mice, implicating the peptide in lipid metabolism and energy balance.

    - **Behavioral Modulation**: Bicknell et al. (1981) observed that Beta-Lipotropin (1-10) administration altered locomotor activity and stress responses in animal models, supporting its role in neuroendocrine regulation.

    Collectively, these findings underscore the peptide’s diverse biological activities and validate its use as a research tool in neuroscience and metabolic studies.

    Usage Guidelines and Best Practices
    For optimal experimental outcomes, researchers should adhere to the following guidelines when using Beta-Lipotropin (1-10), porcine:

    - **Preparation and Storage**: The peptide should be reconstituted in sterile, distilled water or appropriate buffer to the desired concentration. Aliquots should Additional Resources:
    Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 33 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
    https://www.apexbt.com/
    Research Article: PMC11567666